Ligand Bets $47M on AvenCell’s Next-Gen CAR-T Pipeline

Event summary

Ligand commits up to $47M to AvenCell’s CAR-T pipeline via royalties and equity.
Deal funds development of AVC-201 (AML) and AVC-203 (B-cell malignancies).
Royalties range from mid-single-digit to low-double-digit on global sales.
Funding delivered in four tranches tied to clinical milestones.
AvenCell combines CRISPR-engineered allogeneic CAR-T with switchable technology.

The big picture

Ligand’s investment reflects growing confidence in next-generation CAR-T therapies that address limitations of current treatments, particularly around controllability and off-the-shelf availability. The deal underscores the biotech royalty model’s appeal for funding high-risk, high-reward cell therapies, with Ligand positioning itself for potential upside in a competitive oncology landscape. AvenCell’s combination of CRISPR engineering and switchable CAR technology represents a strategic bet on overcoming key barriers in cell therapy adoption.

What we're watching

Clinical Milestones: Whether AVC-201 and AVC-203 meet Phase 1b/1a trial endpoints to unlock remaining tranches.
Royalty Yield: How AvenCell’s commercialization pace impacts Ligand’s long-term royalty returns.
Pipeline Expansion: The pace at which AvenCell applies its platform to new indications beyond hematologic malignancies.